TP53 and cancer: Other approaches target mutp53 downstream signalling pathways including the EGFR signalling pathway with drugs such as NA20 [125] or cetuximab [126] use synthetic lethal approaches to find vulnerabilities of mutant p53 cancer cells that can be targeted with drugs [127,128] or target the capacity of mutp53 to form aggregates using compounds such as ReAcp53 [129,130].